FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average by	urden hours
per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Res	sponses)																	
1. Name and Address of Reporting Person* CANAAN X L.P.				2. Issuer Name and Ticker or Trading Symbol Iterum Therapeutics plc [ITRM]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner					
(Last) (First) (Middle) 2765 SAND HILL ROAD				3. Date of Earliest Transaction (Month/Day/Year) 01/21/2020								_	Officer (give titl	e below)	Other	(specify below	<u> </u>	
(Street) MENLO PARK, CA 94025			4	4. If Amendment, Date Original Filed(Month/Day/Year)							ar)		6. Individual or Joint/Group Filing(Check Applicable Line)Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person					
(City)		(State)	(Zip)				Table	Ι-	Non-Dei	rivativ	e Securitie	s Acquired	, Disposed of,	or Beneficial	ly Owned			
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year			Date, if	(Instr. 8)		(/	4. Securities Acquir (A) or Disposed of (Instr. 3, 4 and 5)		(D) Own		rities Beneficially Reported Transaction(s)		6. Ownership Form:	Beneficial		
				(Mont)	onth/Day/Year)		Code	,	V A	mount	(A) or (D)	Price			Direct (D) Or Indirect (I) (Instr. 4)			
			Table II					ire	currentl	y valio	d OMB co or Benefic	ontrol num		ine form dis	spiayo u			
. =	L	l	1	(e.g., p	uts,			_			le securiti	T .						
1. Title of Derivative Security (Instr. 3)	2. 3. Transaction Conversion Date or Exercise (Month/Day/Yes Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	if Transaction Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		r I	6. Date Exercisable and Expiration Date (Month/Day/Year)			d Amount of g Securities and 4)		9. Number of Derivative Securities Beneficially Owned Following Reported	Owner Form of Deriva Securit Direct or Indi	Owner (Instr.		
				Code	V	(A)	(Σ	ī	Date Exercisab		oiration te	Title	Amount or Number of Shares		Transaction(s (Instr. 4)	(Instr.	4)	
6.500% Exchangeable Senior Subordinated Note due	(1) (2)	01/21/2020		A		\$ 2,000,0	000		(1)(2)	01	/31/2025	Ordinary Shares	2,000,000	\$ 2,000,000	\$ 2,000,00	00 D C		

Reporting Owners

P (0 Y (Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
CANAAN X L.P. 2765 SAND HILL ROAD MENLO PARK, CA 94025	X	X					
Canaan Partners X LLC 2765 SAND HILL ROAD MENLO PARK, CA 94025	X	X					

Signatures

Canaan X L.P., By: Canaan Partners X LLC, its general partner, By: /s/ Janine MacDonald, Attorney-in-Fact	01/23/2020
Signature of Reporting Person	Date
Canaan Partners X LLC, By: /s/ Janine MacDonald, Attorney-in-Fact	01/23/2020
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- On January 21, 2020, Iterum Therapeutics Bermuda Limited (the "Issuer"), a wholly-owned subsidiary of Iterum Therapeutics plc (the "Company"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the "Exchangeable Notes") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and
- (1) a group of accredited investors. Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time. The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per \$1,000
- (2) (continued from footnote 1) principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately \$1.00 per Ordinary Share). The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms.
 - This Exchangeable Note is held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"), and each may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Canaan Fund. Brenton K. Ahrens, a manager and
- (3) member of Canaan X, serves as the representative of the Canaan Entities on the Company's board of directors. Investment and voting decisions with respect to the securities held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent, if any, of its pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.